The approval results for Yifan Pharmaceutical's detox capsules have not been released.

A breakthrough anti-drug capsule based on folk experience, developed through research and exploration, had its phase Ib clinical trial results announced. On August 20th, Yifan Medicine announced that the product had achieved the expected goals. On August 21st, the company's stock price fell, with a drop of over 1% by the time of publication. A person in charge at Yifan Medicine stated that the product had applied for breakthrough therapy on July 15, 2025, and based on the 45 working days after submitting the application, it is expected to receive approval around September 20. "There are still uncertainties about whether the product will be approved for market by the National Medical Products Administration. The company will actively promote the research and development project in accordance with relevant national regulations, and fulfill its obligation to disclose information in a timely manner about the progress of the project," stated Yifan Medicine. Regarding the drop in stock price, the aforementioned person in charge attributed it mainly to industry influence, as the stock prices of the pharmaceutical and biotech industry have adjusted recently after a significant increase.